Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Rheumatology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Psoriasis and Psoriatic Disorders Clinical Trials

A listing of Psoriasis and Psoriatic Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (126) clinical trials

Psoriasis is a chronic, debilitating skin disorder with an estimated prevalence of 2%. Psoriatic skin lesions start with initial pinhead-sized macules and then coalesce into plaques of varying sizes. Despite the great strides in the studies for psoriasis, it is still unclear why psoriatic skin lesions start with small macules ...

Phase N/A

Skin Conditions: Must have moderate to severe plaque-type psoriasis. Name of Medication Being Tested: Etanercept (Enbrel ®) Criteria Needed to be Entered into Study: Children 4 to 17 years of age Must have psoriasis for minimum of 6 months Minimum 10% of total body surface area of psoriasis Must have ...

Phase N/A

The purpose of this research study is to compare the efficacy and safety of a investigational medication versus Enbrel in people with plaque psoriasis.

Phase

The study will include a 4 week screening and washout phase, a 12 week treatment phase and a 4 week observational post treatment followup phase to evaluate safety and disease relapse and rebound. This is an oral medication.

Phase

ActivMed Practices and Research is looking for volunteers to participate in a nationwide study on chronic plaque psoriasis. If you are 18 or older, and have been diagnosed with chronic plaque psoriasis for at least 6 months, you may qualify for this study.

Phase

This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.

Phase

We are studying an injectable medication, secukinumab, in the treatment of moderate to severe plaque psoriasis. Patients will undergo 3 FDG-PET/CT scans during the study to assess inflammation of the large vessels in the body and the effects of secukinumab on this inflammation. The trial lasts for 52 weeks. Initially ...

Phase N/A